CHATPRIVACYDONATELOGINREGISTER
DMT-Nexus
FAQWIKIHEALTH & SAFETYARTATTITUDEACTIVE TOPICS
Mescaline approved for first clinical trial in Switzerland Options
 
Praxis.
#1 Posted : 6/9/2021 11:33:42 PM

DMT-Nexus member

Senior Member

Posts: 682
Joined: 30-Dec-2012
Last visit: 16-Jun-2024
Location: The Twilight Zone
This is news from last month but I only just became aware of it, I figured others here would be interested. Exciting times!

Quote:
MindMed, a leading clinical stage psychedelic medicine company, announced today the approval by the local Swiss ethics committee of the first clinical trial evaluating the acute effects of different doses of mescaline and the role of the serotonin 5-HT2A receptor in mescaline-induced altered states of consciousness (MDR-Study). The study will be conducted at the University Hospital Basel Liechti Lab, in Basel, Switzerland, and is planned to start this month.

...

The present study will primarily help to characterize the subjective effects of different doses of mescaline using modern psychometric outcome measures. It will also explore the role of the 5-HT2A receptor in mescaline-induced altered states of consciousness using the 5-HT2A receptor blocker ketanserin prior to the administration of a high dose of mescaline.

The study will use a double-blind, placebo-controlled, cross-over design with six different dosing conditions. The treatment order will be randomized and counter-balanced.

Dr. Miri Halperin Wernli, President of MindMed, added, "At present there are no modern studies that we are aware of using validated psychometric outcome measures that directly compare different doses of mescaline. With our rigorous clinical trial, we aim to characterize the subjective effects of different doses of mescaline and provide a description of the acute mescaline effects to help clarify the involvement of the 5-HT2A receptor in mescaline-induced altered states of consciousness in healthy people. We believe the drug will have a powerful effect on enhancing the communication between different parts of the brain in unique ways that are otherwise inaccessible to the conscious mind. As we move forward, further studies on patient populations will be targeted to help us distinguish the relationship between the drug-induced experience and its integration into the psychotherapeutic process. The hope is that this will then allow a better understanding of the behavioral changes and the unique effect of these powerful drugs on neuroplasticity."


Full article here.
"Consciousness grows in spirals." --George L. Jackson

If you can just get your mind together, then come across to me. We'll hold hands and then we'll watch the sunrise from the bottom of the sea...
But first, are you experienced?
 

Good quality Syrian rue (Peganum harmala) for an incredible price!
 
Loveall
#2 Posted : 6/10/2021 12:16:15 AM

❤️‍🔥

Chemical expertSenior Member

Posts: 3648
Joined: 11-Mar-2017
Last visit: 05-Nov-2024
Location: 🌎
Cool, thanks for sharing. Mescaline is my personal favorite. Oldest in western culture yet least studied. Looking forward to the results 💚🌵
💚🌵💚 Mescaline CIELO TEK 💚🌵💚
💚🌳💚DMT salt e-juice HIELO TEK💚🌳💚
💚🍃💚 Salvinorin Chilled Acetone with IPA and Naphtha re-X TEK💚🍃💚
 
downwardsfromzero
#3 Posted : 6/12/2021 10:39:41 PM

Boundary condition

ModeratorChemical expert

Posts: 8617
Joined: 30-Aug-2008
Last visit: 07-Nov-2024
Location: square root of minus one
Fantastic, thanks for sharing. I've been wondering how long it would be before some mescaline science would be getting done, and the answer, it seems, is - already!




“There is a way of manipulating matter and energy so as to produce what modern scientists call 'a field of force'. The field acts on the observer and puts him in a privileged position vis-à-vis the universe. From this position he has access to the realities which are ordinarily hidden from us by time and space, matter and energy. This is what we call the Great Work."
― Jacques Bergier, quoting Fulcanelli
 
 
Users browsing this forum
Guest

DMT-Nexus theme created by The Traveler
This page was generated in 0.023 seconds.